Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies

ABSTRACT

Venous thromboembolic disease (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), is an underdiagnosed and underappreciated clinical problem in cancer patients that results in significant patient morbidity and mortality. Standard treatment practices, including the use of intravenous unfractionated heparin (UFH) for initial anticoagulation, the use of oral warfarin for chronic anticoagulation, and the prescription of only 3 to 6 months total therapy, may not be optimal in the setting of active cancer and ongoing anticancer therapy. Challenges of VTE management in cancer patients include heparin resistance because of excess circulating acute phase proteins, increased recurrence rates during warfarin therapy (target international normalized ratio 2 to 3), limited venous access to support therapeutic monitoring, and increased bleeding rates during anticoagulation. Bleeding during anticoagulation is of particular concern in patients with disease- or chemotherapy-related thrombocytopenia, central nervous system involvement with cancer, and recent surgical intervention. Low-molecular-weight heparins (LMWHs) have been shown to be equally effective and safe for initial anticoagulation compared with UFH and have gained popularity, especially in the setting of VTE in cancer. LMWHs have the advantage of less nonspecific protein binding, subcutaneous weight-based dosing without the need for monitoring in most cases, and less heparin-induced thrombocytopenia. Recent clinical trials have shown LMWHs are at least as effective as oral warfarin for long-term anticoagulation in cancer patients. Interest in LMWHs and several new classes of parenteral and oral anticoagulants extends beyond the primary and secondary prevention of VTE and includes antiangiogenesis, metastasis prevention, and survival prolongation.

KEYWORDS

Cancer - thrombosis - heparin - warfarin - hypercoagulability

REFERENCES

• 1 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview.  Haematologica . 1999;  84 437-445
• 2 Brill-Edwards P, Ginsberg J S, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy.  Ann Intern Med . 1993;  119 104-109
• 3 Kakkar V V, Howe C T, Nicolaides A N, Renney J T, Clarke M B. Deep vein thrombosis of the leg. Is there a “high risk” group?.  Am J Surg . 1970;  120 527-530
• 4 Walsh J J, Bonnar J, Wright F W. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labeled fibrinogen-phlebography and lung scanning.  J Obstet Gynaecol Br Commonw . 1974;  81 311-316
• 5 Piccioli A, Prandoni P, Ewenstein B M, Goldhaber S Z. Cancer and venous thromboembolism.  Am Heart J . 1996;  132 850-855
• 6 Gomes M PV, Deitcher S R. Diagnosis of venous thromboembolic disease in cancer patients.  Oncology . 2003;  17 126-139
• 7 Sorensen H T, Mellemkjaer L, Steffensen F H, Olsen J H, Nielsen G L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.  N Engl J Med . 1998;  338 1169-1173
• 8 Deitcher S R, Goldman C K, Ruiter K. Vascular endothelial growth factor (VEGF) levels in patients with idiopathic acute proximal deep venous thrombosis (Abst).  Thromb Haemost . 2001;  86(Suppl) P1517
• 9 Levitan N, Dowlati A, Remick S C. et al . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data.  Medicine . 1999;  78 285-291
• 10 Ottinger H, Belka C, Kozole G. et al . Deep venous thrombosis and pulmonary embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance.  Eur J Haematol . 1995;  54 186-194
• 11 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost . 1997;  78 33-136
• 12 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1993;  69 205-213
• 13 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy.  Int J Hematol . 2001;  73 137-144
• 14 Gordon S. Cancer cell procoagulants and their implications.  Hematol Oncol Clin North Am . 1992;  6 1359-1374
• 15 Rickles F R, Hair G A, Zeff R A, Lee E, Bona R D. Tissue factor expression in human leukocytes and tumor cells.  Thromb Haemost . 1995;  74 391-395
• 16 Bevilacqua M P, Pober J S, Majeau G R. et al . Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1.  Proc Natl Acad Sci USA . 1996;  83 4533-4537
• 17 Deitcher S R, Carman T L, Sheikj M, Gomes M. Hypercoagulable syndromes: evaluation and management strategies in acute limb ischemia.  Semin Vasc Surg . 2001;  14 74-85
• 18 Deitcher S R, Lucore C, Eisenberg P R. Impaired resolution of a massive pulmonary embolus associated with an impaired fibrinolytic response.  Am J Med . 1994;  96 483-484
• 19 Deitcher S R, Erban J K, Limentani S A. Acquired free protein S deficiency asociated with multiple myeloma.  Am J Hematol . 1996;  51 319-323
• 20 Anderson A J, Krasnow S H, Boyer M W. et al . Thrombosis: the major Hickman catheter complication in patients with solid tumor.  Chest . 1989;  95 71-75
• 21 Bona R D. Thrombotic complication of central catheters in cancer patients.  Semin Thromb Hemost . 1999;  25 147-157
• 22 Gould J R, Carloss H W, Skinner W L. Groshong catheter-associated subclavian venous thrombosis.  Am J Med . 1993;  95 419-423
• 23 Kee S T, Kinoshita L, Razavi M K. et al . Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement.  Radiology . 1998;  206 187-193
• 24 Patel V, Igwebe T, Mast H, Karetzky M S. Superior vena cava syndrome; current concepts of management.  N Engl J Med . 1995;  92 245-248
• 25 Prandoni P, Polistena P, Bernardi E. et al . Upper extremity deep vein thrombosis. Risk factors, diagnosis, and complications.  Arch Intern Med . 1997;  157 57-62
• 26 Raad I I, Luna M, Khalil S A. et al . The relationship between the thrombotic and infectious complications of central venous catheters.  JAMA . 1994;  271 1014-1016
• 27 Goodnough L T, Saito H, Manni A, Jones P K, Pearson O H. Increased incidence of thromboembolism in stage-4 breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients.  Cancer . 1984;  54 1264-1268
• 28 Gail M H, Costantino J P, Bryant J. et al . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.  J Natl Cancer Inst . 1999;  91 1829-1846
• 29 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.  J Clin Oncol . 1991;  9 286-294
• 30 Levine M N, Gent M, Hirsh J. et al . The thrombogenic effect of anticancer drug therapy in women with stage-2 breast cancer.  N Engl J Med . 1988;  318 404-407
• 31 Pritchard K I, Paterson A H, Paul N A. et al . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.  J Clin Oncol . 1996;  14 2731-2737
• 32 Zangari M, Siegel E, Anaissie E. et al . Risk factors for deep vein thrombosis in a large group of myeloma patients treated with thalidomide: The Arkansas Experience (Abst).  Blood . 2001;  98 161a
• 33 Deitcher S R, Carman T L. Deep venous thrombosis and pulmonary embolism.  Curr Treatment Options Cardiovasc Med . 2002;  4 223-238
• 34 Scates S M. Diagnosis and treatment of cancer-related thrombosis.  Hematol Oncol Clin North Am . 1992;  6 1329-1339
• 35 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.  N Engl J Med . 2001;  344 626-631
• 36 Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients.  Cancer . 1987;  59 983-985
• 37 Heit J A, Mohr D N, Silverstein M D. et al . Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based chohort study.  Arch Intern Med . 2000;  160 761-768
• 38 Hansson P O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.  Arch Intern Med . 2000;  160 769-774
• 39 Prandoni P, Lensing A W, Cogo A. et al . The long term clinical course of acute deep venous thrombosis.  Ann Intern Med . 1996;  125 1-7
• 40 Prandoni P. Antithrombotic strategies in patients with cancer.  Thromb Haemost . 1997;  78 141-144
• 41 Prandoni P, Lensing A W, Piccioli A. et al . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood . 2002;  100 3484-3488
• 42 Bona R D, Sivjee K Y, Hickey A D, Wallace S B, Wajcs S B. The efficacy and safety of oral anticoagulation in patients with cancer.  Thromb Haemost . 1995;  74 1055-1058
• 43 Bona R D, Hickey A D, Wallace D M. Efficacy and safety of oral anticoagulation in patients with cancer.  Thromb Haemost . 1997;  78 137-140
• 44 Hutten B A, Prins M H, Gent M. et al . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol . 2000;  8 3078-3083
• 45 Levine M N, Hirsh J, Gent M. et al . A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.  Arch Intern Med . 1994;  154 49-56
• 46 Hirsh J, Warkentin T W, Shaughnessy S G. et al . Heparin and low-molecular-weight heparin; mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.  Chest . 2001;  119(Suppl) 64S-94S
• 47 Chan A, Woodruff R K. Complications and failure of anticoagulation therapy in treatment of venous thromboembolism in patients with disseminated malignancy.  Aust N Z J Med . 1992;  22 119-122
• 48 Deitcher S R. Interpretation of the international normalized ratio in patients with liver disease.  Lancet . 2002;  359 47-48
• 49 Hirsh J, Dalen J E, Anderson D. et al . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 2001;  119(Suppl) 8S-21S
• 50 Wells P S, Holbrook A M, Crowther N R. et al . The interaction of warfarin with drugs and food: a critical review of the literature.  Ann Intern Med . 1994;  121 676-683
• 51 Deitcher S R, Carman T L. Heparin induced thrombocytopenia: natural history, diagnosis, and management.  Vasc Med . 2001;  6 113-119
• 52 Levine M N, Lee A Y, Baker R I. et al . A randomized trial of long-term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism (Abstract 298).  Blood . 2002;  100 82a
• 53 Deitcher S R, Kessler C M, Merli G, Rigas J, Lyons R M, Cort S. Secondary prevention of venous thromboembolic events in patients with active malignancy: A randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period.  American Society of Clinical Oncology. 2003; 
• 54 Beyth R J, Quinn L M, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding risk outpatients treated with warfarin.  Am J Med . 1998;  105 91-99
• 55 Levine M N, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment.  Chest . 2001;  119(Suppl) 108S-121S
• 56 Gitter M J, Jaeger T M, Petterson T M, Gersh M D, Silverstein M D. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota.  Mayo Clin Proc . 1995;  70 725-733
• 57 Wester J PJ, de Valk W H, Nieuwenhuis H K. et al . Risk factors for bleeding during treatment of acute venous thromboembolism.  Thromb Haemost . 1996;  76 682-688
• 58 Melissari E, Parker C J, Wilson N V. et al . Use of low molecular weight heparin in pregnancy.  Thromb Haemost . 1992;  68 652-656
• 59 Sanson B-J, Lensing A W, Prins M H. et al . Safety of low-molecular-weight heparin in pregnancy: a systematic review.  Thromb Haemost . 1999;  81 668-672
• 60 Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.  Am J Obstet Gynecol . 1997;  176 1062-1068
• 61 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.  Blood . 1995;  86 1368-1373
• 62 Muir J M, Hirsh J, Weitz J I. et al . A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats.  Blood . 1997;  89 3236-3242
• 63 Bhandari M, Hirsh J, Weitz J. et al . The effects of standard and low molecular weight heparin on bone nodule formation in vitro.  Thromb Haemost . 1998;  80 413-417
• 64 Carman T L, Kanner A A, Barnett G H, Deitcher S R. Neurosurgery thromboprophylaxis following tumor surgery: a survey.  South Med J . 2003;  96 17-22
• 65 Altschuler E, Moosa H, Selker R G, Vertosick F T. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors.  Neurosurgery . 1990;  27 74-77
• 66 Choucair A K, Silver P, Levin V A. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism.  J Neurosurg . 1987;  66 357-358
• 67 Norris L K, Grossman S A. Treatment of thromboembolic complications in patients with brain tumors.  J Neurooncol . 1994;  22 127-137
• 68 Olin J W, Young J R, Graor R A. et al . Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors.  Arch Intern Med . 1987;  147 2177-2179
• 69 Ruff R L, Posner J B. Incidence and treatment of peripheral venous thrombosis in patients with glioma.  Ann Neurol . 1983;  13 334-336
• 70 Schiff D, DeAngelis L M. Therapy of venous thromboembolism in patients with brain metastases.  Cancer . 1994;  73 493-498
• 71 Levine M, Gent M, Hirsch J. et al . A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
• 72 Koopman M M, Prandoni P, Piovella F. et al . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
• 73 Hull R D, Raskob G L, Pineo G F. et al . Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis.  N Engl J Med . 1992;  326 975-982
• 74 Lindmarker P, Holmstrom M, Granqvist S. et al . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  72 186-190
• 75 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 657-662
• 76 Weitz J I. Low molecular weight heparins.  N Engl J Med . 1995;  337 688-698
• 77 Warkentin T E, Levine M N, Hirsh J. et al . Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
• 78 Lensing A W, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis.  Arch Intern Med . 1995;  155 601-607
• 79 Siragusa S, Cosmi B, Piovella, Hirsh J, Ginsberg J S. Low molecular weight heparins and unfractionated heparin in the treatment of patient with acute venous thromboembolism; results of a meta-analysis.  Am J Med . 1996;  100 269-277
• 80 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trails.  Ann Intern Med . 1999;  130 800-809
• 81 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.  Arch Intern Med . 2000;  160 181-188
• 82 Green D, Hull R D, Brant R, Pineo G F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.  Lancet . 1992;  339 1476
• 83 Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone.  Science . 1983;  221 719-725
• 84 Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically.  Haemostasis . 1993;  23(Suppl) 141-149
• 85 Hyers T M, Agnelli A, Hull R D. et al . Antithrombotic therapy for venous thromboembolic disease.  Chest . 2001;  119(Suppl) 176S-193S
• 86 Anand S S, Bates S, Ginsberg J S. et al . Recurrent venous thrombosis and heparin therapy; an evaluation of the importance of early activated partial thromboplastin times.  Arch Intern Med . 1999;  159 2029-2032
• 87 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.  Arch Intern Med . 1997;  157 2562-2568
• 88 Raschke R A, Reilly B M, Guidry J R. et al . The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized, controlled trial.  Ann Intern Med . 1993;  119 874-881
• 89 Merli G, Spiro T E, Olsson C-G. et al . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.  Ann Intern Med . 2001;  134 191-202
• 90 Hainer J W, Barrett J S, Assaid C A. et al . Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study.  Thromb Haemost . 2002;  87 817-823
• 91 Moll S, Ortel T L. Monitoring warfarin therapy in patients with lupus anticoagulants.  Ann Intern Med . 1997;  127 177-185
• 92 Harrison L, Johnston M, Massicotte M P. et al . Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.  Ann Intern Med . 1997;  126 133-136
• 93 Fihn S D, McDonell M, Martin D. et al . Risk factors for complications of chronic anticoagulation.  Ann Intern Med . 1993;  118 511-520
• 94 Choueiri T, Deitcher S R. Why shouldn't we solely use warfarin to treat acute venous thrombosis?.  Cleveland Clin J Med . 2002;  69 546-548
• 95 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.  Thromb Haemost . 1994;  71 7-11
• 96 Pini M, Aiello S, Manotti C. et al . Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.  Thromb Haemost . 1994;  72 191-197
• 97 Das S K, Cohen A T, Edmondson R A, Melissari E, Kakkar V V. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.  World J Surg . 1996;  20 521-527
• 98 Loaciuk S, Bielska-Falda H, Nosczyk W. et al . Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.  Thromb Haemost . 1999;  81 26-31
• 99 Hull R D, Pineo G F, Mah A F, Brant R F. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium (Abstract 556).  Blood . 2002;  100 148a
• 100 Gruel Y, Meyer G, Marjanovic Z. et al . Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer (Abst).  Blood . 2001;  98 707a
• 101 Schulman S, Rhedin A S, Lindmarker P. et al . A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.  N Engl J Med . 1995;  332 1661-1665
• 102 Kearon C, Gent M, Hirsh J. et al . A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med . 1999;  340 901-907
• 103 Schulman S, Granqvist S, Holström M. et al . The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.  N Engl J Med . 1997;  336 393-398
• 104 Zacharski L R, Henderson W G, Rickles F R. et al . Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study Number 75.  JAMA . 1981;  245 831-835
• 105 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of anticoagulation trial.  N Engl J Med . 2000;  342 1953-1958
• 106 Simonneau G, Sors H, Charbonnier B. et al . A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
• 107 Goldhaber S Z. Thrombolysis in pulmonary embolism: a debatable indication.  Thromb Haemost . 2001;  86 444-451
• 108 Arcasoy S M, Kreit J W. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence.  Chest . 1999;  115 1695-1707
• 109 Konstantinides S, Tiede N, Geibel A. et al . Comparison of alteplase versus heparin for resolution of major pulmonary embolism.  Am J Cardiol . 1998;  82 966-970
• 110 Kanter D S, Mikkola K M, Patel S R, Parker S Z, Golhaber S Z. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors.  Chest . 1997;  111 1241-1245
• 111 Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncology patients: a phlebographic study.  Eur J Radiol . 1995;  20 108-111
• 112 Monreal M, Raventos A, Lerma R. et al . Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study.  Thromb Haemost . 1994;  72 548-550
• 113 Ault M, Artal R. Upper extremity DVT: what is the risk?.  Arch Intern Med . 1998;  158 1950-1952
• 114 Fraschini G, Jadeja J, Lawson M. et al . Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.  J Clin Oncol . 1987;  5 672-678
• 115 Schwarz R E, Marrero A M, Conlon K C, Burt M. Inferior vena cava filters in cancer patients: indications and outcomes.  J Clin Oncol . 1996;  14 652-657
• 116 Ihnat D M, Mills J L, Hughes J D. et al . Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?.  J Vasc Surg . 1998;  28 800-807
• 117 Streift M B. Vena cava filters: a comprehensive review.  Blood . 2000;  95 3669-3677
• 118 Athanasoulis C A, Kaufman J A, Halpern E F. et al . Inferior vena caval filters; a review of a 26-year single-centre clinical experience.  Radiology . 2000;  21 54-66
• 119 Millward S F, Peterson R A, Moher D. et al . LGM (Vena Tech) vena caval filter: experience at a single institution.  J Vasc Interv Radiol . 1994;  5 351-356
• 120 Spence L D, Gironta M G, Malde H M. et al . Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters.  Radiology . 1999;  210 53-58
• 121 Decousus H, Leizorovicz A, Parent F. et al . A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.  N Engl J Med . 1998;  338 409-415